North America

A 350-patient prospective study found the handheld 6-lead ECG device detected arrhythmias in 14.9% of patients versus 7.7% for standard ambulatory

The Austin-based biotech said the designation supports its inhaled Caveolin-1 peptide, with Phase 2 interim data expected in the second half of 2026.

Sight Sciences says TearCare is now the first MGD treatment indicated to improve meibomian gland function in evaporative dry eye patients.

The FDA has accepted Teva's NDA for ecopipam with a PDUFA date in Q1 2027, potentially the first new Tourette's therapy in over

The all-stock deal, backed by a $150m oversubscribed private placement, creates a Nasdaq-listed company targeting the first FDA-approved therapy for CRPS-1.

Imamu Tomlinson, CEO of the $2.6bn physician-owned partnership, argues burnout is a systemic failure, not an individual one.

Deep Origin's physics-augmented virtual screening framework achieved a 30.6% hit rate on CD73, against a 0.3% baseline from a prior AI

Pacira BioSciences' intra-articular gene therapy showed durable tolerability and exploratory pain improvements over two years in moderate-to-severe knee osteoarthritis.

Senseonics lifted its full-year 2026 revenue target to $62–66 million after record quarterly revenue and gross margins beat its own guided range.

Aetna has recognised both implant-free MIGS devices as medically necessary for mild-to-moderate open-angle glaucoma, completing major US payer coverage for Sight

Zentalis said FDA alignment on its accelerated approval strategy for azenosertib in Cyclin E1-positive ovarian cancer keeps a 2027 filing pathway open.

Amplia Therapeutics will combine narmafotinib with Lilly's olomorasib in a Phase 1b/2b NSCLC trial starting late 2026, targeting KRAS G12C resistance.

The Tel Aviv-listed biotech secured an oversubscribed PIPE to take its oral PTH(1-34) tablet through a registrational trial and NDA submission.

CG Oncology says PIVOT-006 has accrued most target events, with topline data imminent and a BLA submission for bladder cancer due in Q4 2026.

Clearmind Medicine's Phase I/II trial of CMND-100 can progress to patient cohorts after its safety board unanimously approved advancement following a clean

The $75.4m NIA-funded platform trial will test multiple PSP drugs simultaneously at 50 US sites, enrolling 440 participants over two years.

The MIT spinout will use five-year federal funding to develop a magnetic robotic navigation platform for autonomous endovascular thrombectomy.

The Toronto-listed theranostic company said 12-month Tigris trial data showed a 13.9% absolute mortality reduction versus standard care.

The Irvine-based eye care biotech raised the funds alongside a pending acquisition of Alkeus Pharmaceuticals, with Bain Capital Life Sciences among participating

The UCSF-led platform trial, backed by $75.4m in NIH funding, will test multiple drugs simultaneously across 50 sites in the US.